To access the most recent Pfizer-BioNTech COVID-19 Vaccine Fact Sheets, please scan the QR code provided below. Global websiteTelephone number www.cvdvaccine.com 1-877-829-2619(1-877-VAX-CO19) AVAILABLE ALTERNATIVES COMIRNATY (COVID-19 Vaccine, mRNA) and SPIKEVAX (COVID-19 Vaccine, ...
authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b) (1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner. Please see EUA Fact Sheets atwww.cvdvaccine-...
This press release contains “forward-looking statements” of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, statements concerning: BioNTech’s efforts to combat COVID-19; the...
“BioNTech”) today announced that theU.S. Food and Drug Administration(“FDA”) has approved the supplemental Biologics License Application for individuals 12 years of age and older (COMIRNATY® (COVID-19 Vaccine, mRNA)), and granted emergency use authorization for ...
Learn more about 2024-2025 formula COVID-19 vaccines from BioNTech and Pfizer for individuals 6 months through 11 years of age and 12 years and older. See safety info.
02.04.2025 Pfizer Quarterly Corporate Performance - Fourth Quarter 2024 Press Release(opens in new window) Presentation(opens in new window) Prepared Remarks(opens in new window) Infographic(opens in new window) Transcript(opens in new window) ...
02.04.2025 Pfizer Quarterly Corporate Performance - Fourth Quarter 2024 Press Release(opens in new window) Presentation(opens in new window) Prepared Remarks(opens in new window) Infographic(opens in new window) Transcript(opens in new window) ...
COVID-19 VaccineDistributing Hope to the World Clinical TrialsWhere Science Meets Patients Medicinal SciencesThe Art of Creating New Medicines Podcasts eBooks Newsroom Press Releases Media Asset Library Update & Statements Partnering News Media Contacts About People ExecutivesOur senior-most leadership Board...
Excluding COVID-19 products, Pfizer is now expecting 6% to 8% operational revenue growth in 2023. This reduction of the Company’s previously stated expectation of 7% to 9% non-COVID operational revenue growth reflects certain short-term headwinds, such as the U.S. approval for the Talzenna...
As CEO, Bourla has pushed Pfizer to become a company that is more science-driven and innovative. In response to the COVID-19 pandemic, he drove an investment of more than $2 billion (refusing public funding) to deliver a safe and effective vaccine in eight months rather than the usual ei...